Table 2.
Sample size, duration of trials, dosages of naftidrofuryl or placebo, and aspirin use in studies included in meta-analysis on efficacy of naftidrofuryl compared with placebo for treatment of intermittent claudication
| Studies | Sample size | Duration (months) | Drug dosage (naftidrofuryl or placebo) | No (%) using aspirin | |
|---|---|---|---|---|---|
| Individual patient data* | Per protocol | ||||
| Maass et alw5 | 142 | 104 | 3 | 200 mg three times daily | 94 (66) |
| Adhoute et alw6 | 146 | 118 | 6 | 200 mg three times daily | 88 (60) |
| Kriessman and Neissw7 | 235 | 136 | 3 | 316.5 mg twice daily | 31 (78)† |
| Adhoute et alw8 | 182 | 94 | 6 | 316.5 mg twice daily | 109 (60) |
| Moody et alw9 | 183 | 170 | 6 | 316.5 mg twice daily | 115 (63) |
| Boccalon et alw10 | 182 | 122 | 12 | 200 mg three times daily | 117 (65) |
| Kieffer et alw11 | 196 | 152 | 8 | 200 mg three times daily | 127 (65) |
| Allw5-w11 | 1266 | 896 | 6.3 | — | 681 (64) |
*Intention to treat.
†Accurate data were available for 1071 patients; study by Kriessmann and Neissw7 had reliable data on aspirin use in only 40 patients (data were missing for 195 patients).